Data from an integrated pooled analysis of finerenone across three Phase III trials involving heart failure, chronic kidney disease (CKD), and Type 2 diabetes (T2D) was presented at the 2024 European Association for the Study of Diabetes (EASD) Congress. This analysis was conducted with data from the FIDELIO-DKD2 and FIGARO-DKD3 trials in patients with chronic kidney disease (CKD) and type 2 diabetes and the FINEARTS-HF4 trial in patients with heart failure and mildly reduced or preserved ejection fraction.
Finerenone, marketed as KERENDIA by Bayer AG, is a nonsteroidal mineralocorticoid receptor antagonist (MRA) approved to reduce the risk of sustained eGFR declin...
